Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points.

Background/aims: Screening newborns for congenital adrenal hyperplasia (CAH) is problematic owing to the dynamic changes in serum 17-hydroxyprogesterone (17-OHP) levels following birth. Our study objectives were to determine the accuracy of screening, severity of CAH, and biochemical and clinical outcomes of cases detected by our program which collects specimens at 2 time periods following birth.

Methods: We reviewed all CAH cases detected in the Northwest Regional Newborn Screening Program from 2003 through 2017.